Early Growth Response-1: Friend or Foe in the Heart?

Muntasir Billah1, Adiba Naz2, Rashed Noor3

  • 1Department of Cardiology, Kolling Institute of Medical Research, Northern Sydney Local Health District, Sydney, NSW, Australia; Sydney Medical School Northern, The University of Sydney, Sydney, NSW, Australia.

Insights

Early growth response-1 (Egr-1) has a dual role in cardiovascular disease, acting as both a regulator and potentially offering protection. This review explores its complex functions in heart conditions.

Area of Science:

  • Cardiovascular Biology
  • Molecular Cardiology
  • Gene Regulation

Background:

  • Cardiovascular disease (CVD) is a leading global cause of death and illness.
  • Early growth response-1 (Egr-1) is a key regulator in experimental CVD models.
  • Egr-1 is induced by various cellular stressors relevant to cardiovascular pathology.

Purpose of the Study:

  • To review and summarize the multifaceted roles of Egr-1 in cardiovascular pathobiology.
  • To highlight the emerging understanding of Egr-1's cardioprotective potential.
  • To provide a comprehensive overview of Egr-1's dual nature in cardiovascular disease.

Main Methods:

  • Literature review of experimental and clinical studies on Egr-1 in cardiovascular disease.
  • Analysis of molecular mechanisms underlying Egr-1 regulation and function.
  • Synthesis of current research on the pro- and anti-pathogenic effects of Egr-1.

Main Results:

  • Egr-1 exhibits complex regulatory functions in various cardiovascular disease models.
  • Evidence suggests Egr-1 can mediate both detrimental and beneficial effects on the heart.
  • Specific stimuli and cellular contexts dictate Egr-1's ultimate impact on cardiovascular health.

Conclusions:

  • Egr-1 presents a dual role in cardiovascular pathobiology, with both damaging and protective aspects.
  • Further research is warranted to fully elucidate Egr-1's therapeutic potential in cardiovascular diseases.
  • Understanding Egr-1's complex functions is crucial for developing novel cardiovascular therapies.